Compare XPON & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPON | REVB |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.1M |
| IPO Year | 2022 | N/A |
| Metric | XPON | REVB |
|---|---|---|
| Price | $0.67 | $0.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 235.3K | 113.7K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,417,947.00 | N/A |
| Revenue This Year | $61.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 109.37 | N/A |
| 52 Week Low | $0.60 | $0.76 |
| 52 Week High | $5.50 | $60.48 |
| Indicator | XPON | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 24.14 | 31.56 |
| Support Level | $0.83 | $0.85 |
| Resistance Level | $1.26 | $0.90 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 2.06 | 6.25 |
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).